Hyloris Pharmaceuticals, the Belgian value-added medicines specialist, has unveiled plans to launch its Maxigesic IV (paracetamol/ibuprofen) 1,000mg/300mg solution for infusion in the UK and Ireland in early 2022, after receiving approvals for the non-opioid treatment for post-operative pain.
Hyloris Prepares For UK And Ireland Maxigesic IV Launch
Follows A Pair Of Deals To Bolster Value Added Medicines Pipeline
Value-added medicines specialist Hyloris has announced launch plans for its Maxigesic IV analgesic in the UK and Ireland after receiving approvals for the intravenous paracetamol/ibuprofen solution. The nods follow two deals aimed at bolstering the firm’s pipeline.
